Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Vitamin B6 (Pyridoxine)

The First-Line Answer to Morning Sickness

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

4 human trials, about 12 studies, Multiple RCTs; ACOG practice bulletin. The written rationale for this grade is still being prepared.

FDA
Doxylamine-pyridoxine (Diclegis/Diclectin) is FDA-approved for nausea/vomiting of pregnancy
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

At the doses used for pregnancy nausea, roughly 10 to 25 mg a few times a day, pyridoxine is generally well tolerated, with occasional drowsiness or headache, and drowsiness is more pronounced when doxylamine is added. The real ceiling is dose. The US tolerable upper limit is 100 mg a day; the European Food Safety Authority set a much lower limit of 12 mg a day in 2023, reflecting concern about nerve toxicity. High and prolonged intake is a documented cause of sensory peripheral neuropathy, and a 2025 systematic review raised a possible signal for fetal harm at very high doses, so megadosing should be avoided. Pyridoxine and ginger are options for mild-to-moderate symptoms only; severe, persistent vomiting or hyperemesis gravidarum, which affects a small share of pregnancies, needs medical evaluation rather than self-treatment. Any use in pregnancy, including dosing, should be directed by a qualified obstetric provider.

Vitamin B6, or pyridoxine, is the first medication most obstetric guidance reaches for when a pregnant woman has nausea and vomiting, a condition that touches roughly 70 to 85 percent of pregnancies. The American College of Obstetricians and Gynecologists lists it as first-line, taken alone or with the antihistamine doxylamine before stronger antiemetics. That combination has a long and uncomfortable history: it sold as Bendectin from the mid-1950s, was pulled from the US market in 1983 during a wave of birth-defect lawsuits, and returned in 2013 as Diclegis after cohort studies and meta-analyses found no evidence it caused the defects it was blamed for. Ginger has held up in head-to-head trials as a reasonable alternative for milder symptoms. The one firm caution is dose: the US upper limit is 100 mg a day, and very high intakes have their own risks.

The evidence-based first step for nausea and vomiting of pregnancy, recommended by ACOG, alone or paired with doxylamine.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • First-line treatment of mild nausea and vomiting of pregnancy, as recommended by ACOG
  • Paired with the antihistamine doxylamine for more persistent symptoms, including as the approved Diclegis combination
  • A step that can reduce the need for stronger antiemetics when symptoms respond
  • Part of normal amino-acid and neurotransmitter metabolism, its underlying physiological role

What people get wrong

  • Often saidMorning sickness is just something you have to wait out.

    ActuallyIt is common but treatable, and ACOG describes it as frequently undertreated. Pyridoxine is an inexpensive first step that trials support for mild-to-moderate symptoms, and starting treatment earlier tends to work better than waiting until symptoms are entrenched. A qualified provider can advise on what is appropriate for an individual pregnancy.

  • Often saidAcupressure wristbands are a proven fix for pregnancy nausea.

    ActuallyThe evidence is mixed rather than settled. Some trials of P6 acupressure report relief, others, including a placebo-controlled study during labor, find no difference from sham bands, and reviewers note the benefit may partly reflect placebo. They are low-risk to try, but the trial support is weaker and less consistent than for pyridoxine or, for some women, ginger.

  • Often saidIf a little B6 helps, more will help faster.

    ActuallyMore is not safer. The US tolerable upper limit is 100 mg a day, and a 2025 systematic review by He and colleagues found that women treating pregnancy nausea often exceed it; among the cases reviewed, 164 of 1226 reported neurological symptoms such as tingling, numbness, or unsteadiness. High-dose pyridoxine is a well-documented cause of sensory nerve damage, so treatment should stay within guideline ranges under provider direction.

Who profits, and who pushes back

  • ACOG

    championsPractice Bulletin on nausea and vomiting of pregnancy

    Vitamin B6 is a safe, over-the-counter treatment that may be tried first; doxylamine can be added if B6 alone does not relieve symptoms, and both are safe in pregnancy.

  • FDA

    endorsesApproved doxylamine-pyridoxine (Diclegis, 2013)

    The delayed-release doxylamine-pyridoxine combination is approved for nausea and vomiting of pregnancy in women who do not respond to conservative management, the only drug with that indication.

  • Ginger randomized-trial literature

    endorsesMultiple RCTs

    Ginger has improved nausea and vomiting symptoms for some women in randomized trials and is a reasonable option for milder cases, though responses vary.

  • 2024 high-dose B6 systematic review

    cautionsInt. Journal of Gynecology & Obstetrics

    Exposure to large doses of vitamin B6 during nausea and vomiting of pregnancy may be associated with fetal malformation; treatment should stay within the 100 mg/day upper limit.

  • P6 acupressure evidence

    mixedSystematic review of wristband trials

    Acupressure and acupuncture at the P6 wrist point showed no difference from placebo for nausea and vomiting of pregnancy, despite popular use.

Where the research comes from

Most of the published research on this comes from one place. 70% of it is from NVP affected. Findings that no unrelated group has reproduced are weaker than the study count makes them look.

Share of published research by country of origin.
PlaceShare of published research
NVP affected70%
Unaffected30%

Research published from: Global.

How we got here

Pyridoxine was tried for the nausea of early pregnancy in the 1940s, not long after the vitamin itself was isolated. In 1956 the US Food and Drug Administration approved Bendectin, a combination that originally paired doxylamine and pyridoxine with dicyclomine; the dicyclomine was dropped in 1976. The product was heavily used through the 1970s. In June 1983 its maker stopped selling it in the United States, citing the cost of insuring a drug under a mounting wave of lawsuits that claimed it caused limb-reduction and other birth defects. Numerous cohort and case-control studies, and later meta-analyses, found no increased risk of malformation, so the withdrawal was driven by litigation rather than by the accumulated evidence. The same formula stayed on the market in Canada as Diclectin from 1979 onward. In April 2013 the FDA approved a delayed-release version, Diclegis, restoring an approved first-line option in the United States after three decades.

  1. 1940sPyridoxine first tried for nausea of early pregnancy
  2. 1956FDA approves Bendectin (originally doxylamine, pyridoxine, and dicyclomine)
  3. 1976Bendectin reformulated, dicyclomine removed, leaving doxylamine and pyridoxine
  4. 1979Diclectin (doxylamine-pyridoxine) reaches the Canadian market and stays available
  5. 1983Maker withdraws Bendectin from the US amid birth-defect litigation the evidence did not support
  6. 1995Vutyavanich RCT (342 women) shows 30 mg/day pyridoxine reduces nausea scores
  7. 2013FDA approves delayed-release doxylamine-pyridoxine (Diclegis), Pregnancy Category A
  8. 2018ACOG Practice Bulletin 189 names pyridoxine, alone or with doxylamine, as first-line for NVP
  9. 2023EFSA sets a far lower B6 upper limit of 12 mg/day for adults, based on neuropathy risk
  10. 2025He and colleagues publish a systematic review flagging high-dose B6 hazards in pregnancy

At a glance

Nausea dose
10-25 mg every 8 hr
Tolerable upper limit
100 mg/day
NVP prevalence
~70%
FDA-approved combo
Doxylamine + B6

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Vitamin B6 (Pyridoxine). A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources